STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLDI
  4. [S-3] Calidi Biotherapeutics, Inc. Shelf Registration Statement

[S-3] Calidi Biotherapeutics, Inc. Shelf Registration Statement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-3
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock CLDI logo
Calidi Biotherapeutics Inc

NYSE:CLDI

CLDI Rankings

#8715 Ranked by Market Cap
N/A Ranked by Dividends

CLDI Latest News

Jul 10, 2025
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment
Jul 9, 2025
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
Jul 8, 2025
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
Jun 27, 2025
Calidi Biotherapeutics Announces Shareholder Letter from CEO
Jun 2, 2025
Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting

CLDI Latest SEC Filings

Jul 15, 2025
[Form 4] Calidi Biotherapeutics, Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] Calidi Biotherapeutics, Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] Calidi Biotherapeutics, Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] Calidi Biotherapeutics, Inc. Insider Trading Activity
Jul 14, 2025
[EFFECT] Calidi Biotherapeutics, Inc. SEC Filing

CLDI Stock Data

34.45M
32.65M
7.88%
4.06%
2.99%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO